Federal Circuit Affirms Invalidity of Sage Products’ Chlorhexidine Sterilization Patent in Becton, Dickinson Dispute

Case Overview

The Parties

The Patent at Issue

The patent at the center of this dispute is U.S. Patent No. US10398642B1 (application number US16/231034), covering a “Sterilized chlorhexidine article and method of sterilizing a chlorhexidine article.” Chlorhexidine is a widely used biocide in medical-grade antiseptic products—from skin prep solutions to catheter care kits. Patents in this space typically claim novel formulations, sterilization process parameters, or product configurations that preserve antimicrobial efficacy through sterilization cycles that might otherwise degrade active ingredients.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a straightforward AFFIRMED judgment: “THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED.” The basis of termination was recorded as Unpatentable, confirming that U.S. Patent No. US10398642B1 does not survive the patentability challenge mounted by or in favor of Becton, Dickinson. No damages were assessed—invalidity proceedings eliminate the patent rather than compensate a prevailing party. No specific injunctive relief details were disclosed in the available record.

Verdict Cause Analysis

The verdict cause of Invalidity/Cancellation Action places this case within a well-established category of Federal Circuit appeals where patent owners challenge PTAB final written decisions or district court invalidity rulings. For a chlorhexidine sterilization patent, the most legally plausible invalidity grounds typically include:

• • Anticipation (35 U.S.C. § 102): Prior art disclosing sterilized antimicrobial articles or equivalent sterilization methodologies predating the claimed invention.
• • Obviousness (35 U.S.C. § 103): Combinations of known sterilization techniques applied to chlorhexidine formulations, particularly where the prior art suggests predictable results.
• • Enablement or Written Description (35 U.S.C. § 112): Failure to adequately disclose the full scope of claimed sterilization processes or resulting articles.

The Federal Circuit’s unqualified affirmance signals that Sage Products failed to demonstrate reversible error in the underlying patentability determination—whether through claim construction arguments, challenge to the prior art factual findings, or procedural objections. The specific legal reasoning was not detailed in the available case record, and practitioners seeking full opinion text should consult PACER (Case No. 23-1603) and the USPTO Patent Center for prosecution history.

Legal Significance

This decision carries notable precedential weight for medical device and pharmaceutical chemistry patent litigation in several respects:

• • Sterilization process patents face elevated scrutiny when the underlying chemistry (chlorhexidine antisepsis) is well-established in the prior art—claim differentiation must be both clear and non-obvious.
• • Post-grant challenges remain highly effective against patents in crowded antimicrobial technology spaces, where prior art density is substantial and obviousness arguments are readily constructed.
• • The Federal Circuit’s affirmance without remand reinforces that appellate courts will uphold well-reasoned patentability determinations when the record supports the tribunal’s factual findings on prior art.

Strategic Takeaways

For Patent Holders: Prosecution strategy for sterilization and antimicrobial patents must anticipate post-grant challenges from the outset. Claims should be drafted with explicit distinctions from prior art sterilization parameters, temperature ranges, concentrations, or structural configurations—not merely functional outcomes. Consider building a layered claim portfolio with independent claims of varying scope.

For Accused Infringers: This case affirms that early investment in prior art searches and post-grant petitions (IPR or PGR) can efficiently eliminate problematic patents before costly district court litigation escalates. BD’s apparent success in this challenge demonstrates the value of proactive, pre-litigation IP clearance strategy.

For R&D Teams: Engineers and product developers working with chlorhexidine formulations or sterilization processes should treat this ruling as an FTO signal—the patent covering this specific sterilized chlorhexidine article and method has been canceled. However, related continuation patents or divisional applications in Sage Products’ portfolio may remain active and enforceable; a comprehensive freedom-to-operate analysis is essential before launching competitive products.